Posted by Michael Wonder on 09 Jan 2026
858 Therapeutics announces FDA fast track designation for PARG inhibitor ETX-19477 for the treatment of patients with BRCA mutated, platinum resistant ovarian cancer
8 January 2026 - 858 Therapeutics today announced that the US FDA has granted fast track designation to ETX-19477, the company’s internally discovered PARG inhibitor.
The designation has been granted for the treatment of adult patients with BRCA mutated, platinum-resistant, high grade serous ovarian cancer.
